Related Experiment Video
Updated: Aug 10, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
Published on: August 23, 2024
Lifelong persistence of AML associated MLL partial tandem duplications (MLL-PTD) in healthy adults
Jörg Bäsecke1, Martina Podleschny, Robert Clemens
1Department of Hematology and Oncology, University of Goettingen, Goettingen, Germany. jbaesec@gwdg.de
Abstract:
AML-associated MLL-PTD contribute to leukemogenesis by a gain of function and confer an unfavorable prognosis. Like other leukemia associated aberrations they are also present in healthy adults. To delineate the leukemogenic mechanism we tracked down MLL-PTD in normal hematopoiesis and investigated cord blood samples. MLL-PTD were observed in 56/60 (93%) of all cord bloods. In contrast to AML, the transcript frequency in cord blood was four log scales lower as determined by real-time PCR. The CD34+ progenitor cell, CD33+ myeloid, CD19+ B-lymphoid and CD3+ T-lymphoid subfractions were positive. The ubiquitous presence of MLL-PTD in cord blood implicates a lifelong exposure, not an accumulation during lifetime. Since also present in the stem cell subfraction, these factors seem not to be major determinants in MLL-PTD leukemogenesis.
Insights
MLL-PTD, linked to leukemia, are common in healthy cord blood at low levels. Their presence in stem cells suggests they aren't the sole cause of MLL-PTD driven leukemia.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- MLL-PTD aberrations are linked to acute myeloid leukemia (AML) pathogenesis and poor prognosis.
- These aberrations are also found in healthy adults, suggesting a complex role in leukemogenesis.
- Understanding MLL-PTD presence in normal hematopoiesis is crucial for delineating leukemic mechanisms.
Purpose of the Study:
- To investigate the presence and characteristics of MLL-PTD in normal human hematopoiesis.
- To determine the frequency and levels of MLL-PTD in cord blood samples.
- To explore the role of MLL-PTD in stem cells and progenitor cells in the context of leukemogenesis.
Main Methods:
- Real-time PCR was used to quantify MLL-PTD transcript frequency.
- Cord blood samples were analyzed for MLL-PTD presence.
- Hematopoietic progenitor cell subfractions (CD34+, CD33+, CD19+, CD3+) were examined.
Main Results:
- MLL-PTD were detected in 93% of cord blood samples (56/60).
- Transcript levels in cord blood were significantly lower (four log scales) than in AML.
- MLL-PTD were found across multiple hematopoietic lineages, including CD34+ stem cells.
Conclusions:
- The ubiquitous presence of MLL-PTD in cord blood suggests lifelong exposure rather than accumulation.
- MLL-PTD in stem cell subfractions indicate they may not be the primary drivers of MLL-PTD leukemogenesis.
- Further research is needed to fully understand the role of MLL-PTD in normal hematopoiesis and leukemia development.
Related Concept Videos
Abnormal Proliferation
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Non-LTR Retrotransposons
Cancers Originate from Somatic Mutations in a Single Cell
